Oxaprozin potassium is an orally active and potent inhibitor of COX, with IC 50 values of 2.2 μM and 36 μM for human platelet COX-1 and for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin potassium induces cell apoptosis. Oxaprozin potassium also inhibits the NF-κB activation. Oxaprozin potassium-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties [1] [2].

Oxaprozin (0-100 μM) induces apoptosis in a dose-dependent manner. Oxaprozin increases caspase-3 activity in the activated but not in the resting condition. NF-κB activation is inhibited by Oxaprozin (50 μM). Oxaprozin inhibits activation of the IKK system induced by the reagent IκBα [1]. Oxaprozin (100 μM) induces the strongest proapoptotic effect and significantly increases CD40L-treated monocyte apoptosis. Oxaprozin treatment inhibits CD40L-induced Akt and NF-κB (p65) phosphorylation [2].